Long-term Follow-up Study of FOLFOX6,SOX and mFOLFOX6 Chemotherapy in the Treatment of Advanced Gastric Cancer
Objective To analyze the long-term effects of three chemotherapy regimens FOLFOX6,SOX and mFOLFOX6 in the treatment of advanced gastric cancer. Methods A total of 65 patients with advanced gastric cancer were selected as the research subjects. They were divided into FOLFOX6 group(n =21,FOLFOX6 chemotherapy),SOX group(n =25,SOX chemotherapy) and mFOLFOX6 group(n =19,mFOLFOX6 chemotherapy) according to the chemotherapy regimen. All groups underwent 3 cycles of chemotherapy. Clinical effects and toxicities were compared between the groups. Kaplan-Meier survival curves were plotted according to the follow-up data to analyze the progression-free survival(PFS) and overall survival(OS). Results The ORRs in the FOLFOX6 group,the SOX group and the mFOLFOX6 group were 23. 81％,32. 00％ and 26. 32％,without significant difference among the 3 groups(P >0. 05). The incidence of nausea and vomiting in the SOX group(16. 00％) was significantly lower than that in the FOLFOX6 group(42. 86％) and the mFOLFOX6 group(52. 63％)(P < 0. 05),and the grade of nausea and vomiting was significantly better than that in the FOLFOX6 group and the mFOLFOX6 group(P < 0. 05). The mean progression-free survival time and mean survival time of the FOLFOX6 group was 6 months and 9 months,respectively. The PFS and OS were 44. 0％ and 46. 90％,respectively. The mean progression-free survival time and mean survival time of the SOX group were 8 months and 11 months,respectively. The PFS and OS were 92. 20％ and 87. 6％,respectively. The mean progression-free survival time and mean survival time of the mFOLFOX6 group were 6 months and 9 months,respectively. The PFS and OS were 57. 90％ and 63. 2％,respectively. There were significant differences in PFS and OS among the 3 groups(P <0. 05). Conclusion The 3 chemotherapy regimens FOLFOX6,SOX and mFOLFOX6 can achieve similar clinical effects. However,SOX can reduce nausea and vomiting during chemotherapy,and improve the patients'PFS and OS,with good safety.
万方数据
维普
